Schall, Brown & Schwartz LLP reminded investors of a class action lawsuit against ADMA Biologics alleging violations of §§10(b) and 20(a). The filing signals potential legal overhang for ADMA, but with no specific financial allegations or quantified damages provided in the release, near-term impact is likely limited.
Schall, Brown & Schwartz LLP reminded investors of a class action lawsuit against ADMA Biologics alleging violations of §§10(b) and 20(a). The filing signals potential legal overhang for ADMA, but with no specific financial allegations or quantified damages provided in the release, near-term impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
